Markets

DuPont (DD) Unit Expands Phytase Product Line in Europe

DuPont 's DD Industrial Biosciences unit has launched Axtra PHY 20000 TPT and Axtra PHY 25000 G in Europe, thereby expanding the product line of its award-winning phytase in the European Union (EU). The fastest-acting phytase enzyme is now available in every desired format to all European animal producers.

Proven to be the most efficacious phytase available in the market today, Axtra PHY has been helping animal producers to reduce their production costs as well as their environmental footprint.

The product starts acting earlier in the digestive tract and destroys phytate and its anti-nutrient effects rapidly. This enables more nutrient uptake in the animal. Axtra PHY enables the release and digestion of beneficial nutrients naturally present in the feed by lowering the impact of phytate. As a result the animal producer can significantly lower their feed cost.

In addition to this, Axtra PHY at 1000 FTU (phytase units) can breakdown more than 90% of dietary phytate and decrease feed conversion ratio by up to 10%.

DuPont has outperformed the Zacks categorized Chemicals-Diversified industry over a year. The company's shares have rallied 29.3% over this period, compared with the industry's gain of around 25.8%.

DuPont is well placed to gain from its cost-cutting measures and new product launches. It has numerous new products in its pipeline that should contribute to the top-line growth.

Moreover, the proposed mega-merger with Dow Chemical DOW is expected to deliver cost synergies of around $3 billion. The companies recently secured the U.S. antitrust clearance for the planned merger and expect the closing of the deal to take place in Aug 2017.

E.I. du Pont de Nemours and Company Price and Consensus

E.I. du Pont de Nemours and Company Price and Consensus | E.I. du Pont de Nemours and Company Quote

Zacks Rank & Key Picks

DuPont currently carries a Zacks Rank #2 (Buy).

Other top-ranked companies in the chemical space include BASF SE BASFY and The Chemours Company CC . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

BASF has expected long-term growth of 8.9%.

Chemours has expected long-term growth of 15.5%.

Sell These Stocks. Now.

Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.

See today's Zacks "Strong Sells" absolutely free >>.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

E.I. du Pont de Nemours and Company (DD): Free Stock Analysis Report

Dow Chemical Company (The) (DOW): Free Stock Analysis Report

BASF SE (BASFY): Free Stock Analysis Report

Chemours Company (The) (CC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BASFY CC

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More